Naloxone hydrochloride

Belfort joins forces with Voices For Victoria in response to the call of the Victoria's Voice Foundation to spread awareness of the use of Naloxone to end the worsening fentanyl and opioid crisis. MIAMI, May 29, 2024 /PRNewswire/ -- Author, pop culture icon, and entrepreneur Jordan Belfort has joined forces with Victoria's Voice Foundation to launch an urgent #VoicesForVictoria campaign to end opioid overdose deaths and raise awareness for the importance of overdose reversal sprays like Naloxone. Continue Reading June 6th National Naloxone Awareness Day The initiative has enlisted the "Wolf of Wall Street" legend as one of its celebrity advocates—amongst other public figures—to back Voices For Victoria, a movement initiated by philanthropist Nancy Ross in support of Victoria's Voice Foundation, a non-profit organization with a mission of educating individuals on substance abuse prevention and addiction resources. For Ross—a mother, investigative journalist, philanthropist, and overdose awareness advocate—the fight to save the next generation is one that hits close to home. "As a mom, I want to know that I'm helping to create a better world for my three children," Ross says. "We have to fight to save people from the clutches of this epidemic, and for the many students and community members whom this has already affected." Every single day, nearly 300 people die from a drug overdose in the United States. As one of the campaign's lead advocates, Belfort is helping to lead the charge to help save the next generation. Various initiatives leading up to National Naloxone Awareness Day on June 6 are in the works with Belfort and other high-profile celebrities and government officials. Most recently, the author hosted a live TikTok Q&A session to share critical information about his journey to sobriety and support for the movement. Known for creating content which regularly amasses over 71 million likes, Belfort utilized the live TikTok session to respond to hundreds of incoming inquiries, encouraging viewers to advocate for the observance of June 6th. By kickstarting an empowering social media campaign called #VoicesForVictoria, Ross sends a powerful message to communities across the nation that change is just around the corner, and that no life deserves to go overlooked. Using her platform alongside a suite of celebrity ambassadors has the influence to make a real difference in this fight against opioid overdose. To learn more about Naloxone resources, please visit the official Victoria's Voice Foundation website. MEDIA CONTACT: Michael Glovaski at Gloverse Email: [email protected] Phone: 917.213.4473 SOURCE Voices For Victoria

Significantly expanding access to affordable, life-saving opioid overdose rescue medicine Entered distribution agreement with California; actively engaging with other states and municipalities to expand access BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has begun supplying its over-the-counter (OTC) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg to U.S. retail pharmacies and the State of California. The product is now available for direct distribution to states and municipalities across the U.S. The U.S. Food and Drug Administration approved Amneal’s Naloxone HCI Nasal Spray in April 2024. Amneal’s Naloxone HCI Nasal Spray is a generic equivalent to OTC NARCAN® HCI Nasal Spray, a medication widely used to help treat opioid drug overdoses. The Company also entered into a distribution agreement with California to provide Naloxone HCI Nasal Spray through the CalRx® Naloxone Access Initiative. Amneal expects to have capacity to produce approximately ten million two-packs annually at its New Jersey manufacturing facility, starting in 2025. “Amneal is an industry leader in complex generics with the ability to develop, manufacture and commercialize high-quality medicines that are affordable and accessible. The widespread availability of OTC naloxone will be a critical tool in the fight against the ongoing opioid epidemic. Amneal is proud to be part of the solution,” said Andy Boyer, Executive Vice President, Chief Commercial Officer – Generics. “We are pleased to partner with the State of California on a long-term distribution agreement to make OTC naloxone available to thousands of communities and millions of people. We are actively engaging with other states and municipalities to expand access to this important life-saving product, which is proudly made in America in one of our New Jersey facilities,” said Maryll Toufanian, SVP, Regulatory Strategy and Government Affairs. To learn more about Amneal’s Naloxone HCl Nasal Spray, please visit . About Naloxone Nasal Spray Naloxone Hydrochloride (Naloxone HCI) Nasal Spray is designed to rapidly reverse the effects of a life-threatening opioid emergency by binding to opioid receptors in the brain and blocking the effects of opioids. It can restore normal breathing within two to three minutes in a person whose breath has slowed, or even stopped, as a result of an overdose from opioids including heroin, fentanyl and prescription opioid medications. Amneal’s Naloxone HCI Nasal Spray contains the same active ingredient and dose as NARCAN® Naloxone HCI Nasal Spray, 4 mg. It is available over-the-counter and is easy to carry, and it can be safely used even if opioids are not present in the patient. NARCAN® is a registered trademark of Emergent Operations Ireland Limited. When using this product some people may experience symptoms when they wake up, such as shaking, sweating, nausea or feeling angry. This is to be expected. About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit . Cautionary Statement on Forward-Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the impact of a prolonged business interruption within our supply chain; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our dependence on third-party agreements for a portion of our product offerings; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A common stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof. View source version on businesswire.com: Contacts Investor and Media Contact Anthony DiMeo VP, Investor Relations & Media anthony.dimeo@amneal.com Government Contact Maryll Toufanian SVP, Regulatory Strategy and Government Affairs maryll.toufanian@amneal.com Source: Amneal Pharmaceuticals, Inc. View this news release online at: